Tirzepatide (Mounjaro) in Karachi
The weekly GIP and GLP-1 injection known by the brand name Mounjaro, registered in Pakistan and prescribed here inside a doctor-led weight management programme.
Is tirzepatide right for me?
- For adults with significant weight to lose, typically a BMI of 30 or above, or 27 and above with a weight-related condition, who want the most effective medicine currently available.
- A once-weekly pen injection, started low and increased gradually by the doctor, inside a programme that tracks weight, muscle and side effects.
- In trials, average weight loss of up to around 21 percent of body weight at the higher doses over 72 weeks, the strongest result of any approved medicine in its class.
Two hormones. One injection. The strongest results yet.
Tirzepatide is the first medicine to act on two gut hormone receptors at once: GLP-1, which reduces appetite and slows stomach emptying, and GIP, which improves how the body handles fat and insulin. The combination produces greater weight loss than GLP-1 alone, with many patients finding it gentler on the stomach.
It is known worldwide by the brand name Mounjaro, which is registered in Pakistan, making tirzepatide the most accessible of the new generation weight medicines for patients in Karachi. In the SURMOUNT-1 trial, adults on the higher doses lost around 21 percent of their body weight on average over 72 weeks, and in a direct head to head trial tirzepatide outperformed semaglutide.
Power deserves respect. Tirzepatide is a prescription medicine with real contraindications and side effects, and rapid weight loss without a plan costs muscle as well as fat. The clinic prescribes it inside a supervised programme: screening first, slow titration, protein and strength work, and reviews that keep the loss healthy.
What tirzepatide helps with.
Average losses of 15 to 21 percent of body weight in trials, dose dependent.
→ Appetite and portion controlHunger quietens and smaller meals satisfy, without white-knuckle willpower.
→ Metabolic healthImproves insulin sensitivity, blood sugar, blood pressure and lipids in trial populations.
→ Obstructive sleep apnoeaApproved internationally for moderate to severe sleep apnoea with obesity, after trials showed major improvement.
→Good candidates
- Adults with a BMI of 30 or above, or 27 and above with a condition such as prediabetes, hypertension or sleep apnoea
- Patients who have tried structured diet and exercise without lasting results
- People prepared to commit to titration, follow-up and muscle protection
Not suitable for
- A personal or family history of medullary thyroid cancer or MEN2 syndrome
- Pregnancy, planning pregnancy, or breastfeeding
- A history of pancreatitis
- Severe digestive disorders such as gastroparesis
- Known allergy to tirzepatide or its components
- Severe untreated gallbladder disease, and diabetic eye disease requires specialist review first
How treatment works at the clinic.
Assessment first
Treatment begins after a medical assessment, with a low weekly dose that increases every four weeks as tolerated. The target is not the maximum dose, it is the lowest dose that delivers steady progress with minimal side effects.
Keep the loss healthy
Your programme pairs the medicine with protein targets, strength training and regular reviews, because the goal is fat loss that looks and feels healthy rather than a smaller number achieved by losing muscle. When you reach your goal, maintenance is planned deliberately: a holding dose, a taper, or structured lifestyle support, depending on your case.
Your programme.
History, medicines, contraindication screening and baseline measurements.
Dose increased every four weeks as tolerated, under the doctor's direction.
Scheduled reviews of weight, muscle, side effects and habits.
A deliberate plan for holding your result once you reach it.
Mounjaro or Ozempic?
| What matters | Tirzepatide | Semaglutide |
|---|---|---|
| Receptors | GIP and GLP-1 | GLP-1 |
| Average trial weight loss | Up to about 21% | About 15% |
| Head to head | Greater loss in SURMOUNT-5 | Strong, slightly behind |
| Dosing | Once weekly | Once weekly |
| Availability in Pakistan | Registered (Mounjaro) | Varies by brand |
The common side effects are digestive: nausea, constipation, diarrhoea and reflux, mostly during dose increases. Oral contraceptives may be less reliable around dose escalation, which the doctor will discuss where relevant. Screening and slow titration keep treatment comfortable for most patients.
"Tirzepatide is the most effective weight medicine I can prescribe today. Patients do best when we respect it: proper screening, patient titration and honest follow-up."
Consultant Dermatologist and Laser Specialist. Over 35 years of dermatology, trained in Zurich, practising in Clifton since 1999. Page medically reviewed October 2026.
Tirzepatide and Mounjaro, answered.
Straight answers from the clinic. If your question is not here, ask on WhatsApp.
Ask on WhatsAppMounjaro is the brand name of tirzepatide. Internationally the same molecule is also sold for weight management under the brand Zepbound. The clinic prescribes tirzepatide where appropriate as part of a supervised programme.
Yes. Mounjaro is registered in Pakistan and available through legitimate pharmacy channels with a prescription. Beware of unofficial sellers: counterfeit pens are circulating in every market where demand is high.
In the SURMOUNT-5 head to head trial, tirzepatide produced meaningfully greater average weight loss than semaglutide. That does not make it right for everyone; tolerance, history and availability all matter, and the consultation settles the choice.
Trial averages range from about 15 percent of body weight at lower doses to around 21 percent at the highest dose over 72 weeks. Your result depends on dose, consistency and the habits built around the medicine.
A once-weekly injection under the skin using a pre-filled pen with a very fine needle. We teach you the technique, and it takes less than a minute a week.
Mostly digestive and mostly early: nausea, constipation, diarrhoea and reflux during dose increases. Serious risks are rare and screened for. Most patients settle comfortably once their dose stabilises.
Without a plan, usually yes, as with any weight treatment. Maintenance is designed into the programme from the start so the result outlasts the prescription.
Tirzepatide is also a diabetes medicine, but patients with diabetes need coordinated care. We manage weight treatment together with your physician or endocrinologist rather than in isolation.
Because the pen alone loses muscle along with fat, causes avoidable side effects at the wrong doses, and gives the weight back when it stops. Screening, titration, muscle protection and an exit plan are what turn a drug into a result.
Trials now extend several years with a consistent safety profile, and international regulators have approved it for ongoing use. Long-term treatment still belongs under periodic medical review, which the programme provides.
This page is for education and does not replace medical advice. Tirzepatide is a prescription medicine, provided at the clinic only after an in-person medical assessment and only where clinically appropriate. Mounjaro and Zepbound are trademarks of their manufacturer, referenced for identification only; the clinic is not affiliated with the manufacturer. Product availability and licensed indications vary by market. Individual results vary, and no outcome is guaranteed.
Book a weight management consultation.
Find out whether tirzepatide suits your health profile, and start a programme built to keep the results.
200/1 Clifton 1, Block 5, Clifton, Karachi. Monday to Friday 9:00 to 6:00, Saturday 9:00 to 5:00.
Call or WhatsApp 0301 827 9630